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Intramyocellular lipid accumulation and low lipid oxidative capacity contribute to the formation 
of insulin resistance, but omega-3 polyunsaturated fatty acids (n-3 PUFA) are shown to attenuate 
insulin resistance caused by high levels of saturated fats.  The AMP-activated protein kinase 
(AMPK) promotes lipid oxidation and oxidative gene expression, highlighting its possible role in 
promoting insulin sensitivity by reducing lipid content and improving oxidative capacity.  This 
study evaluated the effects of n-3 PUFA on the AMPK pathway and alterations to lipid content, 
oxidative markers, and insulin signaling proteins in a muscle cell culture model, with the 
hypothesis that n-3 PUFA would attenuate the saturated fatty acid-induced increase in 
intramyocellular lipids and detriments to the AMPK pathway, oxidative markers, and insulin 
signaling.  The findings confirm that n-3 PUFA both attenuate saturated fatty acid-induced 
increases in intramyocellular lipid content and normalize insulin signaling and oxidative 
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CHAPTER 1. INTRODUCTION 
1.1. Background and Significance 
     Emergence of the lifestyle characterized by excessive nutrient intake and low physical 
activity levels has significantly contributed to the worldwide prevalence of overweight and 
obesity (67).  The percentage of obese adults and children in the U.S. has increased to over one-
third and almost one-fifth of the population, respectively, over the past 40 years (55, 67).  
Obesity is an established cause of insulin resistance (21), an early hallmark in the pathogenesis 
of type 2 diabetes (37) and cardiovascular disease (46).  Insulin is the primary anabolic hormone 
that stimulates uptake and storage of nutrients in muscle, liver, and adipose tissue (47), and 
insulin resistance is defined as disturbances in insulin signaling that result in inappropriate 
responses of insulin-stimulated peripheral tissues to the actions of insulin (47) of normal or high 
concentrations (43).     
     The condition of obesity provides constant increased lipid flux into tissues (22), and lipid 
accumulation in non-adipose tissue can lead to cell dysfunction and/or death (87), termed 
lipotoxicity (41, 42, 44, 51, 87).  Implementation of a high fat (HF) diet is associated with 
abnormally high skeletal muscle lipid accumulation (87), which is highly correlated to skeletal 
muscle insulin resistance (65, 76) and is a more robust measurement of insulin resistance than 
body fat percentage, body mass index, and waist-to-hip ratio (22).  However, both endurance-
trained athletes (67) and previously untrained individuals who have undergone an endurance-
training program (60) also display increased fasting intramyocellular lipid content similar to or 
greater than levels found in individuals with type 2 diabetes but conversely possess enhanced 
insulin sensitivity (42, 59, 65), a condition often termed the athlete’s paradox (42).  A low ability 
to oxidize accumulated fatty acids (FA) is an important contributor to formation of insulin 
resistance (44), and skeletal muscle oxidative capacity may be more important in determining 
insulin sensitivity than intramyocellular lipid content (67).  Indeed, the athlete’s paradox (42) 
distinguishes that accumulation of lipids in skeletal muscle is not harmful when adaptations in 
oxidative capacity are maintained and identifies the importance of targeting metabolic treatments 
toward enhancement of oxidative capacity. 
     Formation of insulin resistance is also partially related to the type of FA accumulated in the 
cell (1, 39, 81).  A chronic flux of saturated FA (SFA) are shown to have detrimental effects on 
cells (94) and lead to insulin resistance (39, 52), while exposure to unsaturated FA (UFA) 
prevents (1, 39, 52, 76, 77), attenuates (54), or reverses (19, 46, 64) insulin resistance and when 
co-administered with SFA may prevent against detrimental metabolic effects associated with 
SFA treatment alone (52).  Of particular interest are the long chain omega-3 (n-3) 
polyunsaturated FA (PUFA), such as docosahexaenoic acid (DHA).  Supplementation of a small 
amount of long chain n-3 PUFA for other FA attenuates reductions in insulin sensitivity caused 
by oversupply of lipids (1, 77, 81) and sucrose (19, 46, 64) in cells (1) and metabolically normal 
(11, 20, 76, 77), obese (54) and insulin resistant animals (19, 46, 64).  Omega PUFAs have the 
unique ability to partition FA toward oxidation (6), which identifies a possible role for the 
marine n-3 PUFA to improve insulin sensitivity by promoting skeletal muscle FA oxidation and 
reducing intramyocellular lipid content.   
     An enzyme that may participate in this mechanism is the AMP-activated protein kinase 
(AMPK), which controls systemic energy expenditure, glucose homeostasis, lipid metabolism 
(47), and mitochondrial biogenesis (62).  AMPK is activated by phosphorylation of the 
threonine-172 (Thr172) residue of its α-subunit (90) by an upstream kinase (84).  The level of 
phosphorylated (p-) AMPK parallels the activity of AMPK (49), thus p-AMPKThr172 is an 
indicator of AMPK activity.   
     When activated, AMPK promotes insulin-independent glucose uptake in skeletal muscle (37, 
74) and also centrally regulates fat metabolism both acutely and through long-term 
transcriptional control (75).  Activated AMPK phosphorylates acetyl-CoA carboxylase β at its 
serine-79 residue and inactivates it (13,40, 44, 73, 87, 92, 94, 97), which removes inhibition of 
carnitine palmitoyl transferase-1 and promotes fat oxidation (40, 44, 73, 87, 92, 94, 97).  
Activated AMPK also phosphorylates and activates the PGC1α protein on its threonine-177 and 
serine-538 residues in skeletal muscle, which activates PGC1α gene expression in a feed-forward 
manner (32).  Since PGC1α is a master gene that regulates mitochondrial biogenesis (89), the 
expression and activity levels of the mitochondrial enzymes citrate synthase and cytochrome c 
oxidase provide a method for assessment of oxidative changes downstream of AMPK activity 
(57, 69, 70). 
     Treatments that activate AMPK are shown to improve insulin sensitivity (17, 29, 30, 44, 56, 
72, 91), and the ability of AMPK to enhance fatty acid oxidation and improve oxidative capacity 
identifies its possible value in controlling insulin resistance (4) through reductions in 
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intramyocellular lipid content.  Proper insulin signaling depends on the phosphorylation of 
specific tyrosine residues of the insulin-receptor substrate proteins (IRS) 1-4 (98), and the 
tyrosine phosphorylation of IRS-1 can be blocked by phosphorylation of particular IRS-1 serine 
(Ser) residues, including Ser636 (53), which effectively terminates insulin signal transduction 
(98).  The serine cascade is activated by accumulation of intramyocellular lipid metabolites (53), 
and, as such, the phosphorylation of IRS-1 on Ser636 provides a method for evaluating the 
effects of FA on insulin signal transduction as a marker of skeletal muscle insulin resistance. 
     Long-term FA treatments have been demonstrated to inhibit AMPK (44, 49) and reduce 
insulin sensitivity (44) in rodent skeletal muscle, while n-3 PUFAs are shown to attenuate 
reductions in insulin sensitivity associated with nutrient oversupply (10, 46, 68, 81).  However, 
there has been no published research to date examining the effects of marine n-3 PUFAs on 
AMPK phosphorylation in skeletal muscle cell culture, and there is limited literature (13) 
examining the skeletal muscle effects in vivo.  Elucidating these effects may identify roles of 
marine n-3 PUFAs in improving skeletal muscle lipid homeostasis and contributing to insulin 
sensitivity through dis-inhibition of the insulin signaling pathway.   
1.2. Purpose and Specific Aims 
     AMPK has the ability to regulate cellular lipid status (75) and mechanisms involved in 
oxidative metabolism (32, 40), and n-3 PUFAs promote FA oxidation over storage (6); therefore, 
the purpose of this thesis is to determine if n-3 PUFAs enhance FA oxidation and reduce 
intramyocellular lipid accumulation through activation of the AMPK signaling pathway.  The 
central hypothesis is that long-term DHA treatment of C2C12 myotubes will activate the AMPK 
pathway to improve oxidative metabolism, reduce intramyocellular lipid content and enhance 
insulin signaling. 
 
Specific Aim 1. Determine the long-term effects of palmitate and DHA on AMPK and ACC 
phosphorylation in cultured myotubes. 
Hypothesis 1.1. Long-term palmitate treatment will lead to a reduction in the phosphorylation of 
AMPKThr172 and ACCSer79 in myotubes. 
Hypothesis 1.2. Long-term DHA treatment will increase the phosphorylation of AMPKThr172 and 
ACCSer79 in myotubes. 
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Hypothesis 1.3. Long-term DHA treatment will attenuate the palmitate-induced decrease in the 
phosphorylation of AMPKThr172 and ACCSer79 in myotubes. 
 
Specific Aim 2. Determine the long-term effects of palmitate and DHA on the oxidative capacity 
of cultured myotubes by evaluating the enzyme activity of citrate synthase (CS) and the protein 
expression levels of PGC1α and cytochrome c oxidase (COX) IV. 
Hypothesis 2.1. Long-term palmitate treatment will decrease CS activity and reduce protein 
expression of PGC1α and COXIV in myotubes. 
Hypothesis 2.2. Long-term DHA treatment will increase the activity of CS enhance protein 
expression of PGC1α and COXIV versus control myotubes. 
Hypothesis 2.3. Long-term DHA treatment will attenuate the palmitate-induced decreases in the 
activity of CS and the protein expression of PGC1α and COXIV in myotubes. 
 
Specific Aim 3.  Determine the long-term effects of palmitate and DHA on intramyocellular 
lipid content of cultured myotubes and any related changes in insulin signaling as determined by 
phosphorylation of the insulin receptor substrate 1 (IRS-1) on serine 636/639. 
Hypothesis 3.1.  Long-term palmitate treatment will increase the intramyocellular lipid content 
of myotubes and the phosphorylation of IRS-1Ser636/639. 
Hypothesis 3.2.  Long-term DHA treatment will not change intramyocellular lipid content of 
myotubes from control levels or lead to increases in phosphorylation of IRS-1Ser636/639. 
Hypothesis 3.3.  Long-term DHA treatment will attenuate the palmitate-induced increases in 




CHAPTER 2. REVIEW OF LITERATURE 
2.1. Obesity contributes to the formation of insulin resistance and other chronic diseases 
     Excessive nutrient intake and low physical activity levels significantly contribute to the 
development of overweight and obesity.  Overweight is defined as a body mass index (BMI) of 
25 kg/m2-29.9 kg/m2, and obesity is defined as BMI ≥30 kg/m2 (67).  In the year 2000, the 
percentage of overweight and obese individuals over 20 years old in the United States was 63% 
and 30%, respectively (67).  Furthermore, the prevalence of individuals with extreme obesity 
(BMI ≥40 kg/m2) has increased by 2.8% in men and 6.9% in women as of 2004 (55).  The 
prevalence of obesity in children ages 6-19 years has increased from 4% to 17.1% between 1960-
2004 (55, 67), which is alarming because overweight children are more likely to be overweight 
or obese as adults (25).  Obesity and weight gain are established causes of insulin resistance and 
type 2 diabetes (21), and complications accompanying type 2 diabetes are a major cause of 
disability and death (72).  Obesity and weight gain also increase the risk for many other 
disorders, such as high blood pressure, high cholesterol, asthma, arthritis, and cardiovascular 
disease (67).  The developing obesity epidemic in adults, adolescents, and children across the 
globe will continue to have enormous implications on healthcare and supporting research for 
many years to come.  To reduce the future incidence of these diseases, multiple treatment 
strategies are needed that normalize metabolic control and prevent mortality-associated systemic 
complications (72).   
2.2. Obesity is associated with intramyocellular triglyceride accumulation and formation of 
bioactive lipid species that contribute to insulin resistance 
     Skeletal muscle from obese humans displays an increased quantity of fatty acid (FA) 
transporters in the muscle membrane (71) and increased rates of fatty acid uptake (71, 74) and 
esterification (74), as well as decreased contents of cytosolic FA binding protein for intracellular 
FA transport (50) and reduced rates of FA oxidation (71, 74).  Together these factors lead to the 
obesity-associated phenotypic characteristic of accelerated intramyocellular triglyceride 
synthesis (22).  Skeletal muscle from high-fat fed animals is also shown to have a higher rate of 
intramyocellular triglyceride turnover than that of lean littermates, which leads to chronically 
increased levels of lipid intermediates (22). 
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     When a long chain FA enters the cell, it is rapidly converted to fatty acyl CoA (FACoA) by 
acyl CoA synthetase (22).  This conversion is a required step for entrance into several different 
metabolic processes, which is dictated by the structure of the FA (34).  FACoA can undergo 
elongation and/or desaturation or be formed into complex lipids such as membrane 
phospholipids (34).  FACoA can also be converted to long chain acylcarnitine by carnitine 
palmitoyl transferase-1 (CPT-1) and immediately β-oxidized by the mitochondria, or it can be 
converted to the lipid intermediate diacylglycerol and then to triacylglycerol (TAG or TG) for 
storage (67).  When a stored TG molecule is hydrolyzed, one molecule each of diacylglycerol 
and FACoA is released (22), and, as such, a chronic FA flux can lead to intracellular 
accumulation of diacylglycerol and FACoA (73, 92) either directly through esterification or 
indirectly through TG accumulation and subsequent hydrolysis. 
     Diacylglycerol, long chain FaCoA (22) and ceramides (75) are bioactive lipid signaling 
molecules that can enter and interfere with non-oxidative metabolic pathways (88), leading to 
lipotoxic defects such as formation of insulin resistance (22).  One mechanism underlying 
lipotoxic insulin resistance is through defects in the insulin signaling pathway.  Binding of 
insulin to its transmembrane receptor stimulates the phosphorylation of specific tyrosine residues 
of numerous target proteins, including the insulin-receptor substrate proteins (IRS) 1-4, which 
then associate with other downstream kinases to ultimately mediate the metabolic and growth-
promoting functions of insulin (98).  However, the tyrosine phosphorylation of IRS-1 can be 
blocked by phosphorylation of particular IRS-1 serine (Ser) residues, including Ser636 (53) and 
Ser1101, the latter of which has been associated with IRS-1 degredation (33).  Serine 
phosphorylation of IRS-1 uncouples the protein from its upstream and downstream effectors and 
terminates signal transduction from insulin (98).  It has been demonstrated that the serine 
cascade is activated by accumulation of intramyocellular lipid metabolites (53).  Therefore, the 
phosphorylation of IRS-1 on Ser636 and Ser1101 provides a method for evaluating the effects of 




2.3. AMPK is a master metabolic regulator 
2.3.1. AMPK is important in systemic metabolism 
     The adenosine monophosphate-activated protein kinase (AMPK) pathway is a possible target 
for treatment of insulin resistance (4).  AMPK is a conserved cellular energy gauge (51, 90, 94) 
that serves as a master metabolic regulator by controlling systemic energy expenditure, food 
intake, glucose homeostasis, and lipid metabolism (47).  The protein kinase is activated in 
conditions of energy depletion (17, 40) or metabolic stress (28), such as muscle contraction (17, 
37), exercise (17, 56), and hypoxia (37), and can also be stimulated pharmacologically (44, 56, 
91).  Activation of AMPK acts to conserve cellular energy stores (47, 73) by acutely suppressing 
energy-consuming pathways, such as synthesis of glycogen, cholesterol, and lipids (73), and 
inducing energy-producing pathways, such as glucose uptake (94) and FA oxidation (92, 94).  
AMPK is an important regulator of insulin-independent glucose uptake into tissues by promoting 
glucose transporter 4 (GluT4) translocation to the sarcolemma (37), as well as increased 
expression (47), phosphorylation, and activation (74) of transcription factors regulating the 
GluT4 gene promoter.  Also of particular interest is the ability of AMPK to sense the lipid status 
of a cell (90, 94), independent of cellular energy charge (92). 
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2.3.2. Enzymatic characteristics of AMPK 
     AMPK is a heterotrimeric enzyme formed by α, β, and γ subunits (47, 84, 94).  Each subunit 
has multiple isoforms encoded by separate genes: α1, α2, β1, β2, γ1, γ2, and γ3 (75).  AMPK is 
ubiquitously expressed in mammalian tissues, though some tissue-specific expression is 
observed with the β and γ subunits and the contribution of each α isoform to total AMPK activity 
(4).  Skeletal muscle AMPK complexes mostly contain α2/β2, 80% of which are associated with 
γ1 (73), though glycolytic skeletal muscle predominately contains α2/β2/γ3 complexes (4).   
     The α subunit provides the catalytic activity of AMPK (75, 94) and contributes to AMP 
binding (4).  In skeletal muscle, the α1 subunit is predominately cytoplasmic (84), while the α2 
subunit is located in the cytoplasm and nucleus, and cytoplasmic α2 translocates to the nucleus 
upon stimulation (80), indicating its participation in regulation of gene expression.  The 
regulatory β subunit serves as a docking area for α and γ subunits and also contains a glycogen 
binding domain (75), suggesting a possible role in glycogen feedback regulation of AMPK (4).  
Additionally, the β subunit is important for determining the localization of the α subunit; in 
C2C12 skeletal muscle cells, β2 is shown to aide in the nuclear localization of α2, while β1 
contributes to the return of α2 to the cytoplasm after stimulation (80).  The γ subunit is 
responsible for binding AMP or ATP and thus provides for allosteric control of AMPK (75).  It 
also stabilizes the α subunit and is essential for the catalytic activity of AMPK (4).  The γ1 and 
γ2-isoforms are widely distributed throughout tissues, while the γ3-isoform is highly specific for 
glycolytic skeletal muscle where it plays a role in regulation of carbohydrate metabolism (4) but 
not lipid oxidation (3).  The γ1 isoform is the only γ subunit expressed in C2C12 cells and is 
required for both phosphorylation and nuclear translocation of α2 (80).   
2.3.3. Allosteric modulation and phosphorylation of AMPK 
     Multiple mechanisms contribute to regulation of the AMPK pathway, which varies between 
tissues (47).  AMPK can be regulated through both allosteric modulation and phosphorylation.  
Allosteric activation of AMPK due to increasing concentrations of cellular AMP (94) leads to a 
5-fold increase (84) in the enzymatic activity of AMPK.  AMPK can also be allosterically 
inhibited by the presence of physiological concentrations of phosphocreatine (13, 24) and 
adenosine triphosphate (ATP) (73).  Importantly, allosteric binding of AMP also both facilitates 
the phosphorylation of AMPK on the threonine-172 (Thr172) residue in the activation loop of 
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the α-subunit (90) by an upstream kinase and reduces the inhibitory dephosphorylation of 
AMPKThr172 by its upstream phosphatases (84).  Phosphorylation of AMPK results in a 100-fold 
increase in AMPK activity (23, 84), and when combined with allosteric modulation produces 
greater than 1000-fold activation of AMPK (23).  Since the level of phosphorylated (p-) AMPK 
parallels the activity of AMPK (49), p-AMPKThr172 is commonly used to indicate AMPK 
activity.  Furthermore, phosphorylation of AMPK on its Ser485/491 residues has been associated 
with a decrease in phosphorylation of AMPKThr172 (27), indicating its usefulness as a measure of 
AMPK inactivation.   
     The primary upstream kinase activating AMPK is the tumour suppressor kinase (LKB1) (73, 
75, 84), which phosphorylates AMPKαThr172 in response to increasing AMP concentrations (84).  
The calcium/calmodulin-dependent protein kinase kinase (CaMKK) shows significant homology 
to LKB1 and has also been identified as an AMPK-activator (28).  CaMKK is activated by 
increasing intracellular calcium levels and regulates AMPK independently of the AMP/ATP 
ratio (47).  The primary upstream phosphatases to AMPK are the protein phosphatases (PP) 2C 
(73) and 2A (74).  Adipose tissue also exerts effects on skeletal muscle fuel metabolism, as the 
adipokines adiponectin and leptin have been identified as AMPK-activators (51, 96).  Leptin is 
adipocyte-derived protein hormone secreted in proportion to fat storage content (49) that helps 
regulate energy flow (35).  Leptin has been shown to decrease peripheral TG storage and 
improve insulin sensitivity (47) through improvement of FA oxidation in skeletal muscle cells 
(51, 80).  Adiponectin is a protein also secreted exclusively by adipocytes (64).  Decreased 
expression of adiponectin correlates with insulin resistance, and treatments that stimulate 
production of adiponectin are associated with enhanced insulin sensitivity (64).  Both leptin and 
adiponectin stimulate FA oxidation in skeletal muscle through phosphorylation of AMPKα (96), 
which depends on translocation of the α2 subunit from the cytoplasm to the nucleus (80). 
2.3.4. AMPK contributes to acute and chronic lipid homeostasis 
       AMPK is a central regulator of fat metabolism both acutely and through long-term 
transcriptional control (75).  Classically, AMPK promotes FA oxidation by phosphorylating and 
inactivating acetyl-CoA carboxylase β (ACCβ), the rate-limiting enzyme of malonyl-CoA 
synthesis (40, 44, 73, 87, 92, 94, 97).  The phosphorylation of ACCβ at its serine-79 (Ser79) 
residue is accomplished almost exclusively by AMPK (13), thus p-ACCSer79 is an excellent 
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downstream marker for secondary measurement of AMPK activity.  AMPK also phosphorylates 
and activates malonyl-CoA decarboxylase (MCD), which degrades malonyl-CoA.  Malonyl acts 
as a powerful allosteric inhibitor of CPT-1, which shuttles FACoAs into the mitochondria for β-
oxidation.  The effects of AMPK on ACC and MCD cause a reduction in the level of malonyl-
CoA, subsequently disinhibiting CPT-1 and promoting fat translocation and oxidation (40, 44, 
73, 87, 92, 94, 97).    
     AMPK also regulates long-term lipid metabolism and mitochondrial biogenesis by increasing 
expression of genes involved in FA metabolism (40) and mitochondrial proteins involved in 
oxidation (62).  AMPK is shown to increase FA oxidation in myotubes in a dose-dependent 
manner (40), which occurs with an increase in mRNA expression of the peroxisome-proliferator-
activated receptor (PPAR) γ co-activator 1α (PGC1α) (40) but not PGC1β (32).  PGC1α is a 
master gene that regulates mitochondrial biogenesis (89) and co-activates the PPARα to regulate 
transcriptional control of FA oxidation (40).  AMPK directly phosphorylates and activates the 
PGC1α protein on its threonine-177 and serine-538 residues in skeletal muscle, which activates 
PGC1α gene expression in a feed-forward manner (32).  AMPK activation promotes expression 
of the mitochondrial gene cytochrome c and increases total mitochondrial respiration, which is 
dependent upon the presence of PGC1α (32).  This indicates that activation of AMPK can 
enhance oxidative capacity by improving mitochondrial biogenesis via PGC1α.  AMPK also 
increases mRNA expression of PPARα and its target genes CPT-1 and fatty acid binding protein 





2.3.5. Oxidative capacity is decreased with insulin resistance  
     Reductions in mitochondrial density and activity contribute to reduced oxidative capacity and 
dysregulated lipid metabolism (62) and aide in the development of skeletal muscle insulin 
resistance (47).  A common method for assessment of oxidative capacity is measurement of 
expression and activity levels of the mitochondrial enzymes citrate synthase (CS) and 
cytochrome c oxidase (COX), which are shown to increase in response to aerobic exercise 
training in metabolically normal animals (69, 70) and in insulin resistant humans (57) and are 
decreased in conditions of insulin resistance.  Insulin resistant offspring of individuals with type 
2 diabetes have been shown to exhibit a trend toward lower baseline COX and CS activity levels 
(57), as well as possess 38% lower mitochondrial density and 50% lower expression of COX 
versus insulin-sensitive individuals, which is associated with 60% greater intramyocellular lipid 
content (53).  Maximal COX activity was also reduced by almost 50% after 6 weeks of high-fat 
and high-sucrose feeding of male Wistar rats versus control animals (5).   
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2.3.6. Activation of AMPK enhances oxidative capacity   
     The ability of AMPK to reduce skeletal muscle TG content by stimulating FA oxidation (44, 
47) and enhancing lipid oxidative capacity (4) is important in its distinction as a positive 
regulator of insulin sensitivity (44, 47).  The compounds 5-aminoimidazole-4-carboxamide 
ribonucleoside (AICAR) (91) and metformin (44) are pharmacological stimulators of AMPK.  
AICAR potently activates AMPK (91) in cells upon formation of the adenosine analogue ZMP 
(40, 47), while AMPK is an indirect target of metformin (32).  While it is possible that AICAR 
may also affect other AMP-sensitive enzymes, it is commonly used to examine the effects of 
AMPK activation on cellular processes (9, 17, 29, 30, 37, 56, 61, 62).  AICAR is shown to 
increase skeletal muscle FA oxidation (32, 40) and PPARα (40), PGC1α (32, 40), CPT-1, and 
FABP3 mRNA expression (40), and both AICAR and metformin increase the mRNA expression 
of cytochrome c and uncoupling proteins-2 and -3 (32) in skeletal muscle cells.   
     Treatment of male Sprague-Dawley rats with AICAR for 4 weeks significantly increased 
cytochrome c protein content in white quadriceps as well as the activity of CS, succinate 
dehydrogenase, and malate dehydrogenase in white quadriceps and soleus muscles (93).  
Furthermore, administration of oral metformin for 14 days to male Wistar rats increased PGC1α 
protein content and CS activity in soleus and red and white gastrocnemius muscles, as well as 
cytochrome c protein content in the soleus (79).  These studies examining the effects of AICAR 
and metformin on AMPK activity and subsequent FA oxidation and mitochondrial oxidative 
capacity identify the possible value of AMPK-activating treatments in controlling insulin 
resistance (4) through changes in lipid homeostasis. 
2.4. Fatty acid treatments alter skeletal muscle AMPK 
     FA treatments have been shown to both activate (78, 92, 94) and repress (44, 83) AMPK 
phosphorylation and activity, but the outcome is dependent upon the type of FA and the length of 
treatment.  The saturated fatty acid (SFA) palmitate comprises between 30-40% of FA in the 
plasma (94) and is commonly used (7, 8, 14-16, 18, 29, 31, 39, 41, 52, 56, 59, 63, 65, 83, 85, 90, 
92, 94) along with the monounsaturated fatty acid (MUFA) oleate (1, 7, 8, 18, 39, 41, 52, 59, 65, 
92, 94) and omega-6 (n-6) polyunsaturated fatty acid (PUFA) linoleate (39, 92) to study the 
effects of  different FAs on metabolic markers.  Acute palmitate (10, 76) and linoleate (76) 
treatments have been shown to promote skeletal muscle AMPK and ACC phosphorylation (15, 
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92), while chronic treatment with palmitate (94) and palmitoyl-CoA (83), as well as long-term 
high-fat (HF) feeding with primarily SFA (44, 49), have been shown to repress AMPK in 
skeletal muscle and other cell types. 
2.4.1. Acute fatty acid treatments stimulate AMPK activity 
     Treatment of L6 myotubes for 1 hour with 0.25 mM of SFA palmitate or PUFA linoleate 
significantly increased AMPK activity, phosphorylated (p-) AMPKThr172, and p-ACCβSer218 with 
no changes in cellular energy charge.  Both palmitate and linoleate pre-treatments increased 
subsequent palmitate oxidation rates (92).  In a similar study, L6 myotubes incubated for 1 hour 
with 0.001-0.8 mM palmitate demonstrated a dose-response increase in p-AMPKαThr172 and p-
ACCSer79 levels, which was significant with as little as 0.01 mM palmitate and peaked with 0.4 
mM palmitate at 3.5-fold for AMPK and 4.5-fold for ACC.  Furthermore, as palmitate 
concentration increased so did its oxidation (15).  Similar effects are also observed in a different 
cell type, as acute treatment of bovine arterial endothelial cells (BAECs) with palmitate resulted 
in increased p-AMPK and p-ACC versus control-treated cells (94).  Together these data indicate 
that acute treatment with FA leads to activation of AMPK and inactivation of ACC to promote 
FA oxidation, which supports an acute feed-forward mechanism where increased lipid 
availability enhances FA oxidation to allow non-adipose cells to adapt to increasing FA flux 
without initially changing lipid storage capacity. 
2.4.2. Long-term fatty acid treatments repress basal AMPK activity but may not affect 
the ability of AMPK to be chronically activated 
     More applicable to the condition of obesity is long-term FA treatment that increases cellular 
and tissue lipid concentrations and detrimentally affects metabolic pathways.  For example, 
although palmitate treatment led to an initial activation of p-AMPK and p-ACC levels in 
BAECs, these values returned to basal levels by 5 hours, and both basal and AICAR-stimulated 
p-AMPK and p-ACC were significantly decreased with long-term treatment for 40 hours, which 
was not due to increased ATP from palmitate oxidation or reduced AMPK or ACC expression 
(94).  This clearly identifies the opposing effects of FA on AMPK and ACC phosphorylation in 
acute versus chronic conditions and distinguishes that the same effects may occur in skeletal 
muscle.   
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     Indeed, animal HF feeding studies mimic the Western diet of nutrient oversupply and have 
been shown to inhibit AMPK in rodent skeletal muscle (44, 49).  Male Wistar rats fed a 22% fat 
diet of predominately lard for 5 months demonstrated significant decreases in basal total- and 
phosphorylated-AMPKα protein, AMPKα2 mRNA, and p-ACC protein versus chow-fed animals 
in the gastrocnemius muscle, which was associated with decreased basal and insulin-stimulated 
glucose uptake during hyperinsulinemic clamping.  However, animals receiving oral metformin 
during the last month of feeding displayed an attenuation of insulin resistance as evidenced by 
significant increases in the glucose infusion rate (GIR) during clamping, which was associated 
with 162% and 39% increases in basal p-AMPKαThr172 and p-ACC levels, respectively (44).  
This data suggests that although basal AMPK activity and expression is decreased in skeletal 
muscle of HF-fed animals, they maintain the capacity to improve these levels through chronic 
pharmacological activation, which is also associated with enhanced insulin sensitivity.   
     Young male FVB mice fed a 55% fat diet of predominately lard for 5-12 weeks showed 
impaired AMPK phosphorylation and activity in response to leptin administration in the soleus 
muscle but demonstrated unimpaired AMPK activation by AICAR (49), identifying that these 
animals were leptin resistant but still maintained the ability to sense cellular energy charge.  
Furthermore, another group (36) reported that 3-week old male Wistar rats fed a 50% fat diet for 
4 weeks were insulin resistant but did not display significantly different hypoxia-stimulated p-
AMPK levels than chow-fed animals.  These studies suggest that HF-feeding does not affect the 
ability of skeletal muscle AMPK to become activated by agents other than leptin, indicating that 
these pathways may be targeted to induce positive metabolic effects.  However, feeding studies 
of over 14 weeks are considered long-term in rats (46); therefore, further studies are needed to 
identify the ability of  skeletal muscle AMPK to be activated after chronic HF-feeding.  Chronic 
SFA treatment of BAECs led to reduced basal and AICAR-activated AMPK levels (94), 
highlighting the need for these studies in skeletal muscle. 
     Together these data suggest that short-term HF feeding does not alter the ability of AMPK to 
be activated and leads to adaptations in FA oxidation to meet cellular needs, while long-term HF-
feeding leads to decreased basal AMPK activity and overcomes the adaptive capacity of the 
muscle for FA oxidation when unaided by pharmacological activators or stress-inducing 
conditions.  These studies did not examine the effects of PUFA supplementation on basal and 
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stimulated p-AMPK levels, which may identify cellular role(s) of PUFAs in metabolic regulation 
of lipid metabolism through alteration of skeletal muscle AMPK activity. 
2.5. Cellular effects of fatty acids depend on their structures 
2.5.1. Saturated and unsaturated fatty acids differentially affect cellular metabolism   
     The effects of dietary FA on health depend not only on the quantity but also on the nature of 
the fatty acids (48).  A chronic flux of SFA is demonstrated to have detrimental metabolic effects 
in cells (52, 65, 94) and skeletal muscle (39) and is associated with formation of insulin 
resistance (39, 52), while exposure to unsaturated fatty acids (UFA) prevents (1) (11, 39, 52, 76, 
77), attenuates (54), or reverses insulin resistance (19, 46, 64).  Interestingly, there is also 
evidence that UFA co-administered with SFA offers prevention against detrimental metabolic 
effects associated with SFA treatment alone, improving lipid homeostasis (7) and promoting 
insulin sensitivity (52). 
     Myotubes incubated with palmitate showed increased accumulation of diacylglycerol and 
formation of insulin resistance, while cells incubated with oleate had increased TG levels and no 
changes in insulin sensitivity.  Co-incubation of palmitate + oleate also led to increased TG 
content and prevented insulin resistance in a dose-dependent manner.  Furthermore, palmitate 
treatment led to a reduction in PGC1α mRNA expression, while cells treated with oleate alone 
and palmitate + oleate had PGC1α expression levels similar to control values and actually 
demonstrated an approximate 7-fold increase in CPT-1 mRNA expression (7).  This data 
indicates that SFA treatment induces insulin resistance and downregulates the expression of the 
mitochondrial regulator PGC1α, while UFA treatment leads to maintenance of mitochondrial 
biogenesis and improvement in FA oxidation capacity and can actually prevent detrimental 
effects of SFA on these parameters. 
2.5.2. Omega-3 polyunsaturated fatty acids enhance insulin sensitivity 
     In addition to the positive effects of the MUFA oleate on prevention of insulin resistance, a 
great deal of literature has examined the metabolic effects of PUFAs.  The n-6 PUFA linoleic 
acid and the omega-3 (n-3) PUFA linolenic acid are considered essential fatty acids because they 
cannot be synthesized by mammals and must be consumed from dietary sources (66).  
Metabolism of linolenic acid gives rise to two other FA (12) of particular interest in regards to 
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insulin resistance, the long chain n-3 PUFAs eicosapentaenoic acid (EPA; C20:5 n-3) and 
docosahexaenoic acid (DHA; C22:6 n-3).  EPA and DHA are primarily found in fish, shellfish, 
and sea mammals and are sparse or absent in plants and land animals (45), and at least 30 
marketed species of Mediterranean fish and shellfish provide significant sources of n-3 PUFAs 
by containing high levels of EPA and DHA (58).  In the literature these PUFAs are often 
administered in the form of fish oil (FO) (20).  Conversely, n-6 PUFAs are found in foods of 
animal origin and in vegetable oils (66).  Currently more than 85% of the total dietary PUFA 
intake in Western diets is of the n-6 moiety, while consumption of n-3 PUFAs has declined (48).  
This may be one contributor to the rise in obesity-associated disease, as high intake of n-6 
PUFAs has been associated with childhood obesity (48) and may lead to hyperinsulinaemia and 
insulin resistance in adults (95).   
     In 1987, Storlein et al. (77) demonstrated that substituting a small amount of n-3 PUFAs in 
the form of FO for n-6 PUFAs in a HF diet attenuated reductions in insulin sensitivity observed 
with a HF-diet alone.  Since this discovery, a plethora of research has been aimed at identifying 
the mechanisms underlying these beneficial effects.  Although it has been demonstrated that n-3 
PUFA improve components of the insulin-signaling pathway in skeletal muscle (20, 38, 81), 
their effects outside of the insulin-signaling pathway remain unclear.  PUFAs have the unique 
ability to partition FA toward oxidation (6), which identifies a possible role for the marine n-3 
PUFAs to improve skeletal muscle insulin sensitivity by promoting FA oxidation and reducing 
of intramyocellular lipid content.  Therefore, focus will be maintained on studies identifying 
effects of n-3 PUFAs on blood and skeletal muscle lipid parameters to assess possible changes in 
FA flux, lipid synthesis, and oxidative metabolism as they relate to alterations in insulin 
sensitivity.  Little research is available on the effects of n-3 PUFAs on skeletal muscle oxidative 
capacity, though one study did report that male Wistar rats fed a HF diet containing 10% n-3 
PUFA + 18% SFA exhibited 48% and 83% increases in skeletal muscle acyl-CoA oxidase 
activity and mRNA expression, respectively, versus rats fed a HF diet containing 28% SFA.  
This was associated with a normalization of the GIR during hyperinsulinemic clamping, 
indicating an enhancement of systemic insulin sensitivity (86). 
     Aside from direct measurements of FA oxidation and mitochondrial proteins and enzymatic 
activities, changes in intramyocellular lipid contents are indicators of the possible effects of n-3 
PUFAs on fatty acid metabolism in skeletal muscle.  Male Wistar rats were fed a control diet 
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(CON), a 70% fat diet (HF), or a HF diet with either 10% replacement of SFA with n-3 PUFAs 
from FO (HF+FO) or 18.5% replacement of SFA with the n-6 PUFA gamma-linolenic acid from 
borage oil (HF+GLA) for 3 weeks.  The HF diet led to increased fasting insulin levels and post-
prandial free FA, TG, and glycerol levels, which were normalized by FO but not GLA 
supplementation.  Interestingly, the plasma TG levels in the HF+FO group were even 
significantly lower than the control group by about 50%.  The GIR during hyperinsulinemic 
clamping was about 60% lower in HF versus control animals and was significantly increased 
with FO supplementation. Skeletal muscle TG contents were similar in control and HF+FO 
groups and were significantly lower than in animals fed HF or HF+GLA diets (68).   These data 
clearly indicate the hypolipidemic effect of n-3 PUFAs in blood and skeletal muscle and its 
association with improved systemic insulin sensitivity.  
     Other studies have also assessed the effectiveness of n-3 PUFA supplementation in 
prevention of insulin resistance.  Male Wistar rats were fed diets containing 18.5% fat, composed 
of either 8% corn oil (control diet, CD) or 1% corn oil + 7% cod liver oil (CD+CLO) for 1 
month.  CLO is high in the n-3 PUFAs EPA and DHA (82).  The CD+CLO group exhibited 
significantly lower plasma TG and insulin levels and significantly higher GIR during 
euglycemic-hyperinsulinemic clamping compared to CD-fed animals (11), demonstrating an 
association between short-term CLO supplementation and prevention of insulin resistance in 
metabolically normal rats through improvements in systemic glucose utilization and reductions 
in plasma TG levels.  
     Since CLO supplementation prevented fat-induced insulin resistance in normal animals, the 
same group (46) evaluated the possibility that CLO supplementation could reverse diet-induced 
insulin resistance.  Young male Wistar rats were fed a sucrose-rich diet (SRD, 8% corn oil) for 6 
months to induce dyslipidemia and insulin resistance, after which the animals were split into 2 
groups and fed for 2 more months with either the same SRD or one where the 8% corn oil was 
replaced by 1% corn oil + 7% CLO (SRD+CLO).  CLO supplementation restored gastrocnemius 
TG content to control levels and significantly reduced diacylglycerol and FACoA content versus 
SRD-feeding (46), suggesting either improvement in FA oxidation or reduction in TG synthesis.  
Additionally, the SRD was associated with increased fasting plasma TG, FFA, and glucose 
concentrations and led to over 50% reduction in GIR during clamping versus the CD, while CLO 
supplementation elicited values similar to CD-fed animals (46).  These studies indicate that CLO 
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supplementation is associated with normalization of skeletal muscle lipid content and improved 
glucose homeostasis during fasting and insulin-stimulated conditions. 
     Mustad et al. (54) expanded the literature by examining the possibility of different n-3 PUFA 
supplements (α-linolenic acid [ALA], EPA, or DHA) to improve glucose metabolism and insulin 
sensitivity in HF-fed ob/ob mice.  Mice were fed MUFA-rich diets [43-45% fat, 37-39% CHO, 
and 18% protein] with n-3 PUFA percentages of either 1.2% (MUFA), 24.6% (ALA), 36.6% 
(EPA), or 34.7% (DHA) for 4 weeks.  EPA and DHA groups had lower plasma TG and free FA 
levels than the MUFA group, which is similar to other findings (19, 46).  The plasma glucose 
concentration 2 hours post-meal was also significantly reduced by 40-50% in all n-3 PUFA 
groups compared to MUFA-fed mice, indicating improved glucose utilization in response to 
feeding (54) which may have occurred through activation of the AMPK pathway. 
2.6. Polyunsaturated fatty acids may alter skeletal muscle AMPK to improve insulin sensitivity 
     It is clearly established that treatment with n-3 PUFAs exerts positive effects on insulin 
sensitivity in skeletal muscle (1, 11, 19, 26, 46, 54, 76, 77), which has been shown in cell culture 
(1), in metabolically normal (11, 76, 77), obese (54), and insulin resistant (19, 46, 64) animals, 
and in humans (26).  In several cases this improvement is associated with reduced plasma and 
intramyocellular lipid levels (11, 46, 54, 68, 86), indicating reduced lipid flux to tissues and 
either reduced TG synthesis or increased FA oxidation.  AMPK-activating treatments are also 
established to improve glucose and lipid homeostasis and enhance insulin sensitivity (17, 29, 30, 
44, 56, 72).  However, there is limited literature examining the cellular effects of marine n-3 
PUFAs on AMPK, especially in skeletal muscle.  AMPK is an important sensor of cellular lipid 
status (90, 94) and regulator of FA oxidative metabolism (47, 92, 94) and mitochondrial 
biogenesis (62).  Furthermore, omega PUFAs have been identified to partition FA from storage 
toward oxidation in liver and skeletal muscle (6).  Therefore, it is possible that marine n-3 
PUFAs exert positive effects on AMPK phosphorylation, which leads to improvements in FA 
oxidation and possibly mitochondrial oxidative capacity to reduce intramyocellular lipid storage.  
There has been no published research to date examining the effects of marine n-3 PUFAs on p-
AMPK in skeletal muscle cell culture, although the outcomes of other FA treatments on AMPK 
activity have been examined (15, 92).  Furthermore, only two in vivo studies have examined the 
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effects of marine n-3 PUFAs on AMPK, with one in liver (78) and the other in skeletal muscle 
(13).   
     Male Sprague-Dawley rats were fed an initial 7-day high-glucose, no fat diet, which 
decreased liver p-AMPKThr172 levels and AMPK activity by 80% and approximately 50%, 
respectively, versus pre-meal values, with similar reductions in p-ACC levels and no change in 
total AMPK protein concentration.  This is not unexpected, as the same group demonstrated a 
depression in AMPK phosphorylation and activity with re-feeding a high-carbohydrate diet after 
fasting (2).  For the next 7 days, rats were fed the same high-glucose diet but supplemented with 
10 grams of either MUFA [triolein, 99% omega-9] or PUFA [35% EPA and DHA] per 100 
grams of diet.  Fasted p-AMPKαThr172 values were unchanged, while p-AMPKThr172 and p-
ACCβSer79 levels were reduced with both diets 2 hours following the final meal.  However, this 
reduction was greater with the MUFA diet than the PUFA diet, as both postprandial PUFA p-
AMPKThr172 and p-ACC levels were approximately double MUFA levels.  Furthermore, MUFA 
feeding was associated with significantly lower AMPK activity levels than PUFA feeding (78).  
This indicates that although AMPK was not affected in the post-absorptive state, n-3 PUFAs did 
exert a greater activating effect on AMPK and ACC phosphorylation and AMPK activity than 
MUFAs.  Moreover, the PUFA group demonstrated lower postprandial levels of fatty acid 
synthase (FAS) mRNA and higher CPT-1 mRNA expression than the MUFA group (78), 
indicating a greater shift from lipogenesis toward FA oxidation with n-3 PUFA feeding.   
     While any FA treatment could be expected to upregulate levels of AMPK activity, 
phosphorylated AMPK and ACC, FA transport proteins, and oxidative enzymes after a high-
glucose, no-fat diet, merely due to their renewed presence in the tissues, an n-3 PUFA treatment 
was more effective than a MUFA treatment in doing so.  This is promising because it suggests 
that mechanism(s) other than simply the law of mass action contribute to the ability of n-3 
PUFAs to activate AMPK and ACC.  Whether they may do this directly by acting on AMPK or 
indirectly by acting on upstream AMPK regulators still needs to be determined.  Furthermore, 
this study is considered short-term (46) because the MUFA and PUFA supplements were 
administered for only one week, and it would be interesting to observe the chronic effects of n-3 




     In response to this study, Dobrzyn et al. (13) evaluated the effects of feeding a 5% fat diet of 
either PUFA from FO or MUFA from triolein for 14 days on AMPK activity in heart, liver, and 
skeletal muscle of mice.  They found no changes in p-AMPKThr172 levels in FO-fed animals 
versus control in any tissue (13).  While these results suggest that PUFAs do not activate AMPK 
in mouse tissues, no changes were observed in liver p-AMPKThr172, which is contradictory to the 
previous findings (78) that n-3 PUFAs are more effective in stimulating liver AMPK than 
MUFAs and indicates that confounding factors may be present.  For one, these animals were 
metabolically challenged with stearoyl-CoA desaturase 1-deficiency, making the results difficult 
to compare to other studies in metabolically normal animals.  Additionally, this PUFA diet 
contained 5% fat with 25% EPA/DHA content, versus 10% fat and 35% EPA/DHA content in 
the study by Suchankova et al. (78), indicating that the n-3 PUFA composition of the diet may 
not have been great enough to observe positive effects on AMPK activity. 
     HF-feeding was shown to reduce skeletal muscle AMPK phosphorylation and activity, which 
correlated with reductions in systemic insulin sensitivity (44).  Additionally, administration of 
marine n-3 PUFAs attenuated reductions in p-AMPK, p-ACC, and CPT-1 mRNA and increased 
suppression of FAS in the liver of normal animals (78).  These data prompt further investigation 
of the effects of marine n-3 PUFAs on skeletal muscle AMPK phosphorylation and activity to 
identify if the improvement in insulin sensitivity observed with n-3 supplementation is at all 
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CHAPTER 3. RESEARCH METHODS 
 
Materials.  Mouse C2C12 myoblasts were purchased from American Type Culture Collection.  
Fetal calf serum (FCS) was purchased from Atlas Biologicals.  ITS Liquid Media Supplement, 
palmitic acid sodium salt, cis-4, 7, 10, 13, 16, 19-docosahexaenoic acid (DHA) oil, insulin, 
Ponceau S red, 99% triethyl phosphate, and a citrate synthase assay kit (Cat# CS0720) were 
purchased from Sigma.  BSA was purchased from Santa Cruz Biotechnology.  SDS-PAGE pre-
cast gels were purchased from Invitrogen, and nitrocellulose membranes and an RC DC protein 
assay kit (#500-0121) were purchased from BioRad.  Antibodies were purchased from Cell 
Signaling Technology, and goat anti-rabbit and goat anti-mouse horseradish peroxidase-
conjugated IgG were purchased from Jackson ImmunoResearch Laboratories, Inc..  Enhanced 
chemiluminescence (ECL) was purchased from Pierce, and advanced ECL was purchased from 
Amersham Biosciences.  ReBlot Plus Strong Solution was purchased from Millipore.  X-ray film 
was purchased from Phenix Research Products.  Oil Red O powder was purchased from Fluka 
Analytical. 
 
Cell culture. Mouse C2C12 myoblasts were seeded in six-well (35-mm) plates in DMEM (4.5 g/L 
D-glucose, with L-glutamine, pyridoxine hydrochloride, 110 mg/L sodium pyruvate, and 3.7 g/L 
sodium bicarbonate) supplemented with 10% FCS and 1% penicillin and streptomycin (PS) and 
maintained in a humidified incubator at 37ºC in an atmosphere of 5% CO2.  Cells were grown to 
~95% confluence and then induced to differentiate into myotubes by incubation in serum- and 
PS-free DMEM supplemented with 1% ITS Liquid Media Supplement for 3 days.  After 
differentiation, cells were maintained in DMEM with 2% FCS until experimental treatment.   
     Palmitate and cis-4, 7, 10, 13, 16, 19-docosahexaenoic acid (DHA) oil were dissolved in 
ethanol and diluted in DMEM containing 2% BSA to reach desired fatty acid (FA) 
concentrations.  For dose-response experiments, myotubes were treated separately with palmitate 
and DHA in 0mM, 0.1mM, 0.25mM, 0.5mM, 0.75mM, and 1.0mM concentrations in media 
containing 2% FCS, and 2% BSA for 24 hours.  For time-response experiments, myotubes were 
treated with media containing 2% FCS, 2% BSA, and 0.5mM palmitate or 0.1mM DHA for 24, 
48, and 96 hours.  For all subsequent experiments, myotubes were treated with media containing 
2% FCS, 2% BSA, and 0.5mM palmitate, 0.1mM DHA, 0.5mM palmitate plus 0.1mM DHA, or 
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no FA for 96 hours, and fresh media was provided every 48 hours.  For insulin-stimulation 
experiments, myotubes were washed once with PBS and treated with 100nM insulin in DMEM 
for 15 minutes. 
 
Image capture and cell size.  Images from myotubes that were treated for 48 and 96 hours were 
visualized at x20 magnification using an inverted light microscope (Nikon) and captured with a 
Spot RT camera and Spot Software (Diagnostic Instruments).  Myotube diameter was measured 
from randomly selected microscope fields from three different wells (35 mm) of control and 
treated conditions (12 wells total per time-point) using Image J software (37). Six diameters were 
measured per myotube, and ten myotubes were measured per well, except in the case of 
palmitate-treated cells, where if ten myotubes were not present, all of the remaining myotubes 
were measured. 
 
Evaluation of phosphorylated and total proteins.  Cells were harvested by scraping in 1 x SDS 
sample buffer (1% SDS, 6 mg/mL EDTA, 0.06 M Tris (hydroxymethyl) aminomethane (pH 6.8), 
2 mg/mL bromophenol blue, 15% glycerol, and 5% β-mercaptoethanol).  Protein concentrations 
were quantified in duplicate using an RC DC protein assay and averaged for determination of 
Western blot loading volumes.  Aliquots (30 μg/ml) of harvested C2C12 cells were resolved by 
10%, 3-8%, or 4-12% SDS-PAGE using pre-cast gels.  Control and treated cells were loaded on 
the same gel to account for possible variations between blots, as well as a standard molecular 
weight marker to verify protein sizes.  Proteins were transferred to a nitrocellulose membrane 
and stained with Ponceau S red to confirm transfer.  Membranes were probed with primary 
antibodies against phosphorylated T172 for AMPKα, S79 for ACC, S636/639 for IRS-1, S473 
for Akt, S21/9 for GSK3α/β, S240/244 for rpS6, or for total protein expression of PGC1α and 
COX-IV.  Membranes were then probed with anti-species conjugated horseradish peroxidase 
secondary antibodies.  Blots were developed as described below.  Where appropriate, 
membranes were stripped with 1X ReBlot Plus Strong Solution and probed with antibodies 
against total protein expression of AMPKα, ACC, Akt, GSK3β, β-tubulin, and GAPDH.  Signals 
for GAPDH were developed by enhanced chemiluminescence and for all other proteins by 
advanced ECL, and bands were visualized by exposing the membranes X-ray film.  Digital 
records of the films were captured with a Kodak 290 camera, and bands were quantified as 
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optical density x band area by a one-dimensional image analysis system (Eastman Kodak) and 
expressed in arbitrary units normalized relative to the loading control. 
 
Oil red O stain.  Oil Red O (ORO) staining was performed as a visual marker to evaluate the 
effects of FA treatments on intramyocellular lipid content after 48 and 96 hours (15).  Cells were 
grown, differentiated, and treated with FA as previously described.  A 5g/L ORO stock solution 
was prepared in a 3:2 ratio of 99% triethyl phosphate to distilled water.  For staining, the stock 
solution was diluted to a 36% ORO/TEP working solution then filtered three times by passing 
through a syringe with a 0.45 micron filter tip.  Culture dishes were washed three times with PBS 
and myotubes fixed with 10% formalin then washed with distilled water and stained with 36% 
ORO/TEP.  Stained myotubes were rinsed with distilled water and visualized.  Intramyocellular 
lipid content was quantified by measuring fluorescence (excitation 485nm, emission 530nm) of 
the stained lipids, and values were normalized to protein content per well, which was determined 
using a commercially available kit. 
 
Citrate Synthase Activity.  To evaluate the effects of FA treatments on mitochondria oxidative 
metabolism after 96 hours, the activity level of citrate synthase (CS) was evaluated using an 
assay kit according to the manufacturer’s instructions. Cells were grown, differentiated, and 
treated with FA as previously described.  Cells were lysed in 200 μL of CelLytic M Reagent, 
centrifuged at 12,000 x g, and the supernatant transferred to a chilled test tube.  Protein content 
was determined as described previously.  The sample reaction mixture was prepared with the 
appropriate volumes of 1 x Assay Buffer, 30 mM Acetyl CoA Solution, and 10 mM DTNB 
solution and added to 10μL of sample in a 96-well plate.  The spectrophotometer was set at 412 
nm, and absorbances were measured at 0, 1, and 2 minutes.  After determining the baseline 
absorbance of the reaction mixture for 2 minutes, 10 mM Oxaloacetate Solution was added to the 
reaction, and the absorbance was read for another 2 minutes to determine total CS activity.  All 
samples were evaluated in triplicate.  CS activity for each sample was calculated per 
manufacturer instructions and was normalized to protein content.  A CS positive control was 




Statistical Analyses.  All results represent the mean percent change ± standard error for a 
minimum of three cell culture experiments (n=3) in triplicate, with exception to insulin-
stimulation experiments which consists of two experiments (n=2) in triplicate.  One-way 
ANOVA with Tukey post-hoc analysis was used to evaluate differences for each variable 
between treatments, and statistical significance was set at P ≤ 0.05.  Analyses were conducted 




CHAPTER 4. RESULTS 
 
Selection of fatty acid doses and treatment duration. To choose fatty acid concentrations and 
time-points for study, dose- and time-response curves were generated to evaluate both myotube 
morphology and levels of phosphorylated and total AMPK, since it was the primary protein of 
interest.  Dose-response curves (Figure 1) indicated that 0.75mM and 1.0mM palmitate 
treatments and 1.0mM DHA had high phospho-to-total AMPK ratios; however, there were few 
or no cells left on the plate after 24 hours with palmitate treatment in these concentrations, and 
the idea with the DHA treatment was not to bombard the cells with DHA, but to add a small 
amount of polyunsaturated fatty acids in comparison to the saturated fatty acids as done 
previously (18, 21, 38, 39, 41).  Therefore, we chose 0.5mM palmitate and 0.1mM DHA, as they 
provided the next greatest phosphorylation of AMPK without loss of cellular integrity and gave a 
polyunsaturated:saturated fatty acid ratio of 0.2, which is similar to previous studies using a ratio 
of 0.25 (21).   
     To determine the duration of treatment, we evaluated the myotube morphology and size.  
Since there were no apparent changes in morphology after 24 hours (Figure 2A), we focused on 
48 and 96 hour time-points for measurement of myotube diameter (Figure 2B).  Palmitate 
treatment decreased myotube diameter by 25% (p=0.052) after 48 hours and over 90% (p<0.001) 
after 96 hours versus control.  However, DHA maintained myotube morphology and diameter; 
adding DHA to the palmitate treatment increased myotube diameter by almost half (p=0.004) 
after 48 hours and over 100% (p<0.001) after 96 hours versus palmitate alone.  Because the most 
dramatic change in myotube morphology and size without complete loss of palmitate cells 
occurred at 96 hours, we chose this time-point to conduct subsequent measurements.  
Furthermore, since a treatment effect on β-tubulin levels at timepoints longer than 24 hours was 
observed, all subsequent western blot measures were normalized to GAPDH protein expression 
because it did not demonstrate a time x treatment effect. 
 
Palmitate-induced detriments to myotube morphology and size are attenuated by DHA.  To 
determine if maintenance of myotube morphology with DHA treatment was due to activation of 
the AMPK pathway, we measured phosphorylation of AMPKα on Thr172, which is required for 
its activation (40), and total AMPK protein expression (Figure 3A).  Phospho-AMPKαThr172 
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levels were not significantly different between treatments, but addition of DHA to the palmitate 
treatment led to 106% higher (p=0.05) total AMPK levels than palmitate alone, which was 
associated with a 5.7-fold increase (p=0.032) in the AMPK ratio in palmitate versus control 
conditions.   
     To determine if the activation of AMPK with palmitate treatment was propagated 
downstream, we examined its cytosolic target, acetyl Co-A carboxylase (ACC) (Figure 3B).  
AMPK inhibits ACC through phosphorylation on Ser79, which reduces lipid synthesis and 
allows for fatty acyl-CoA entry into the mitochondria (43).   While all fatty acid treatments led to 
increases in phospho-ACCSer79 levels, there were no significant changes between treatments or 
versus control.  These data are consistent with the phospho-AMPKαThr172 data (Figure 3A).  The 
total ACC levels mirrored its phosphorylated levels and were also no significantly different 
between treatments; therefore, the ACC ratio was also similar between treatments (Figure 3B). 
 
Palmitate treatment increases intramyocellular lipid content of myotubes.  Since AMPK is 
considered to be a regulator of lipid homeostasis in skeletal muscle (45), next we evaluated the 
intramyocellular lipid content with different fatty acid treatments.  Myotubes were stained with 
Oil red O, which indicates the levels of all neutral lipids.  There was a 400% (p<0.000) increase 
in auto fluorescence of Oil red O stained myotubes with palmitate treatment when normalized to 
average protein content per treatment.  Intramyocellular lipid content returned to control levels in 
DHA-palmitate co-treated myotube cultures (Figure 4). 
 
DHA maintains protein abundance of oxidative markers in palmitate-treated myotubes.  Since 
AMPK is also known to activate transcription for long-term regulation of lipid homeostasis (20), 
the total protein expression of its nuclear target, PGC1α, was measured.  PGC1α is a 
transcription factor responsible for expression of genes involved in oxidative metabolism.  
Palmitate treatment decreased PGC1α protein expression by 69% versus control (p=0.4), 
although the addition of DHA to the palmitate treatment completely attenuated this effect by 
increasing its protein expression 165% (p=0.017) versus palmitate treatment alone (Figure 5A). 
This suggests that DHA preserves oxidative metabolic capacity in palmitate-treated cells.  To 
determine if the improvement in PGC1α expression with DHA was matched downstream by an 
increase in oxidative metabolism, we measured CS activity as a marker of the tricarboxylic acid 
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cycle and COX-IV protein expression as an indicator of the of the electron transport chain.  We 
found disparate effects on these oxidative markers. CS activity demonstrated a small but 
significant 3% increase (p<0.05) with palmitate treatment versus all other conditions, and 
addition of DHA to palmitate had similar CS activity as control cells (Figure 5B).  However, 
palmitate treatment led to a 34% decrease (p=0.297) in COX-IV protein expression, while 
addition of DHA returned COX-IV expression to control levels (Figure 5C). 
 
DHA attenuates palmitate-induced detriments in the insulin signaling pathway.  To determine 
if changes in intramyocellular lipid content and markers of oxidative metabolism with DHA 
treatment led to alterations in the insulin signaling pathway, the inhibitory serine 
phosphorylation site of the insulin receptor substrate (IRS) 1 was examined.  All fatty acid 
treatments elevated p-IRS-1Ser636/639 by 2-3-fold, although these increases were not significant 
from each other or control conditions (Figure 6).  Because changes were noted in markers of 
lipid content and oxidative metabolism with the different treatments, which were associated with 
disparate effects on myotube morphology and size, investigation of insulin signaling was 
continued further downstream of IRS-1 to examine activation of Akt, GSK3β, and rpS6.  The 
phosphorylation of Akt on Ser473 was measured because it is required for its activation (13), and 
previous research has demonstrated it to be decreased with palmitate treatment in skeletal muscle 
(18, 29, 33).  Although not statistically significant, Akt phosphorylation and total protein were 
decreased by at least one-third and phospho-GSK3β by almost half with palmitate treatment 
versus control conditions, while addition of DHA completely attenuated these decreases (Figure 
7A&B).  Contrary to the Akt data, however, total GSK3β levels remained unchanged (Figure 
7A&C).  The effects of DHA on palmitate treatment continued all the way downstream to rpS6; 
palmitate decreased phospho-rpS6Ser240/244 levels to approximately 25% of control, while addition 
of DHA increased its activation by 7-fold (p=0.017) (Figure 8). 
     To observe the responsiveness of the signaling pathway, myotubes were stimulated with 
100nM insulin for 15 minutes, a dose and time consistent with previous literature performing 
immunoblotting (5) and chosen to elicit a maximal signaling response.  Overall, DHA again 
attenuated the decrements of palmitate treatment (Figure 9).  Phospho-Akt was reduced by half 
by palmitate treatment, although not statistically significant, and total Akt protein expression was 
only ~25-45% of the other treatments (p<0.02).  Activation of GSK3β was also decreased 55-
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85% by palmitate (p<0.03).  Addition of DHA attenuated all of these decreases to approximately 
70% of control values (p<0.03).  Together these data indicate a complete rescue of basal- and a 
partial but significant attenuation of insulin-stimulated- signaling by adding the omega-3 
polyunsaturated fatty acid DHA to the saturated fatty acid palmitate treatment. 
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CHAPTER 5. DISCUSSION 
 
     The central aim of this thesis was to determine if long term administration of n-3 PUFAs 
enhances FA oxidation and reduces intramyocellular lipid accumulation compared to palmitate 
treatment through activation of the AMPK signaling pathway in skeletal muscle cell culture.  
The central hypothesis was that long-term DHA treatment of C2C12 myotubes would activate the 
AMPK pathway to improve oxidative capacity, reduce intramyocellular lipid content, and 
enhance insulin signaling.  The main finding of this thesis is that after 4 days of treatment in a 
cell culture model of a high fatty acid environment, DHA attenuated the negative effects of 
palmitate on myotube size and morphology, some measures of oxidative metabolism, 
intramyocellular lipid content, and insulin signaling independently of AMPK activation.  Overall 
these data confirm previous findings (6, 8, 18, 21, 36, 39, 41) that omega-3 polyunsaturated fatty 
acids have the ability to prevent detrimental effects of saturated fatty acids.   
     A most-striking initial finding of this research is that myotube morphology and size were 
markedly and differentially altered by palmitate and DHA.  Long-term treatment of cells with 
palmitate altered the typical morphological properties of myotubes; after 2 days myotubes were 
significantly smaller in diameter than with either control or DHA conditions, and after 4 days 
very few myotubes remained and most cells lost adherence to the plate.  However, this effect was 
completely attenuated by co-treatment with DHA, as this group demonstrated a 12% increase in 
diameter even over control cells after 4 days. 
     To determine if the changes in myotube morphology were associated with changes in protein 
expression and activation of signaling proteins involved in lipid metabolism, we measured 
AMPK phosphorylation and total protein expression.  Contrary to our hypothesis, DHA does not 
appear to exert its positive effects through activation of AMPK since all fatty acid treatments led 
to non-significant 2-3-fold increases in phosphorylated AMPK.  However, there was a significant 
difference in the AMPK ratio between treatments, which was due to decreased total AMPK 
levels in palmitate-treated cells.  The total AMPK data are supported by previous findings that 
total AMPKα protein levels were decreased by approximately 60% after 5 months of high fat 
feeding in rodents.  However, phospho-AMPKThr172 levels were also decreased (22), which is 
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contrary to our data and could possibly reflect the differences between animal and cell culture 
models.     
     The high AMPK ratio in the palmitate treated cells indicates that most of the remaining total 
AMPK present in the cells was activated.  Given the morphology of the cells treated with 
palmitate, it is most-likely that the myotubes were undergoing apoptosis and/or death and were 
trying to produce energy by activating the master energetic regulator that stimulates ATP-
producing processes (44).  While cell death was not measured, our lab has previously 
demonstrated that 0.75mM palmitate treatment of myotubes for 16 hours lead to a 7-fold 
increase in DNA fragmentation versus control-treated cells (29), and the activation of AMPK via 
AICAR treatment in differentiating C2C12 myoblasts led to increased DNA fragmentation and 
caspase-3 cleavage (46).  These data along with the morphological characteristics of the cells 
suggest that the palmitate-treated cells were undergoing apoptosis.   
     Moreover, addition of DHA to the palmitate treated cells maintained the AMPK phospho:total 
ratio near control levels, and the morphological and cell size data of these cells was similar to 
control-treated myotubes.  Together these findings support that DHA did not differentially 
increase AMPK phosphorylation but was able to maintain the AMPK ratio through attenuation 
of the decrease in total AMPK and possibly contribute to the attenuation of cellular atrophy and 
death.  Our phospho-AMPK data may be different from the findings of Liu et al. (22) because we 
were examining a more extreme model of atrophy/cell death than their animal model. 
     The cytosolic downstream target of AMPK, ACC, similarly demonstrated nonsignificant 2-4-
fold increases in phosphorylation but did not display decreased total ACC levels, leading to 
similar ratios of phosphorylated to total ACC in all conditions.  These data suggest that ACC-
mediated fatty acid oxidation was not different between treatments and that lipid synthesis may 
also be similar because two of the primary cellular metabolic fates of long chain fatty acyl Co-A 
molecules are β-oxidation or conversion to diacylglycerol and triacylglycerol for storage (35).   
     To determine if the fatty acid treatments led to differential changes in lipid storage, 
intramyocellular lipid content was examined.  Because activation of AMPK decreases expression 
of genes involved in lipid synthesis (3), an increase in the phosphorylated:total AMPK ratio 
suggests that intramyocellular lipid content should be decreased with palmitate treatment.  This 
is not what the data indicated, as intramyocellular lipid content was substantially increased in the 
palmitate-treated cells versus the other conditions, which is consistent with our hypothesis.  
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Pimenta et al. (30) also observed 2.5-to-3-fold increases in phosphorylation of AMPK and ACC 
after palmitate treatment, which was associated with approximately 3-fold increases in 
intramyocellular lipids.  Moreover, apart from measurements of AMPK activation, the conditions 
of obesity (24, 31) and high fat-feeding (10, 38) are shown to increase intramyocellular lipid 
content.  These data indicate that although DHA was able to reduce accumulation of 
intramyocellular lipids when added to the palmitate treatment, this alteration was not through 
activation of the AMPK pathway.  It is possible that the reduced intramyocellular lipid content in 
the control and both DHA treatments was due to an increase in lipid oxidation versus palmitate 
conditions, resulting in lower net lipid content versus palmitate-treated cells.   
     We hypothesized that addition of DHA to the palmitate treatment increases the ability of the 
cell to deal with the influx of fatty acids by improving oxidative metabolism; therefore, the 
transcription factor PGC1α was examined.  PGC1α is located in the nucleus and promotes 
expression of genes involved in oxidative metabolism (2, 16, 17, 27).  Addition of DHA to the 
palmitate treatment maintained PGC1α near control levels, which indeed suggests that DHA may 
maintain palmitate-induced decreases in oxidative metabolism to improve utilization of 
intramyocellular lipids and attenuate cellular atrophy and/or death.  In line with this, there are 
data to suggest a relationship between PGC1α expression level and cell size.  Sandri et al. (34) 
demonstrated a sharp decrease in PGC1α mRNA expression in diabetes-induced atrophied 
muscle, which they suggested may be triggered by insulin resistance.  They also showed that 
maintenance of PGC1α levels conferred protection from muscle atrophy by inhibiting 
transcription of atrophy-related genes, which they noted may be an indirect effect of a PGC1α-
mediated increase in mitochondrial content or β-oxidative metabolism (34).  Our data support 
these findings and suggest that maintenance of PGC1α and resulting differences in oxidative 
metabolism may contribute to cell size and morphology in a high fat environment. 
     One consideration that must be made when interpreting the results of this study deals with the 
apparent uncoupling between the AMPK ratio and the phosphorylation of ACC and protein 
expression of PGC1α, which would both be expected to increase with an increase in the AMPK 
ratio.  The data of Suzuki et al. (40) may partially explain the disparate effects on the cytosolic 
and nuclear targets of AMPK in our study.  They demonstrated that phosphorylation of Thr172 
on the α2 subunit is critical for activity of AMPK and that the regulatory β subunit determines its 
subcellular localization.  Upon leptin stimulation of C2C12 myoblasts, the AMPKα2/β1 complex 
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remained in the cytosol while the α2/β2 complex translocated to the nucleus after 1 hour, 
returned to the cytosol after 3 hours, and localized to both the nucleus and cytosol after 6 hours 
(40).   Since both nuclear and cytosolic targets of AMPK rely on phosphorylation of α2 but were 
not affected similarly in our study, it is unlikely that a decrease in α2 could be solely responsible 
for the decrease in PGC1α expression.  It is possible that α1 levels could be decreased with 
palmitate treatment, as the antibody for total AMPK targeted both α subtypes, but this is also 
unlikely because α1 does not translocate to the nucleus (40) which is where the most detrimental 
effects occurred to AMPK substrates with palmitate treatment.  Therefore, palmitate treatment 
could have altered both protein expression of the AMPK α2 and β2 subunits, leading to a 
decrease in nuclear translocation of the complex and thus activation of transcription factors in the 
nucleus.  This would not necessarily affect phosphorylation of ACC, as the β1 subunit is 
primarily responsible for localizing the complex to the cytosol, and given the long time-period, 
the biphasic response of the α2/β2 complex would localize some of the remaining α2/β2 to the 
cytosol to phosphorylate ACC.  Further examination of the effects of FA on the β subunits are 
needed to clarify this possibility. 
     To determine if markers of oxidative metabolism were maintained similarly to PGC1α 
content by addition of DHA to palmitate treatment, the activity of CS and protein expression of 
COX-IV were examined as markers of the tricarboxylic acid cycle and electron transport chain, 
respectively.  Contrary to our hypothesis, DHA did not increase CS activity either alone or with 
palmitate treatment.  Conversely, there was a small increase in CS activity with the palmitate 
treatment, although most-likely not enough to translate to a physiologically-significant increase 
in oxidative metabolism.  This finding does go along with previous data demonstrating an 
increase in CS activity in skeletal muscle after high fat feeding (42) and in the muscle of obese 
animals (12).  Ultimately, however, these data indicate that DHA did not rescue myotube 
morphology by increasing enzyme activity of the initial step of the tricarboxylic acid cycle.  
Alternatively, DHA did maintain COX-IV protein levels versus palmitate treatment alone.  These 
data support the idea that maintenance of PGC1α also maintains mitochondrial content in the 
myotubes (34), which would result in preservation of oxidative enzyme protein content instead 
of necessarily increasing enzyme activity to maintain oxidative capacity and ultimately myotube 
morphology.   
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     Furthermore, Muoio and colleagues (16) found that high-fat-induced insulin resistance in 
animals was associated with decreased expression of PGC1α and accumulation of intramuscular 
acylcarnitines (from β-oxidation), while PGC1α overexpression in myocytes favored formation 
of CO2 (complete fatty acid oxidation).   They suggest that nutrient oversupply leads to an 
increase in lipid oxidation where the flux of β-oxidative by-products overcomes the capacity of 
the tricarboxylic acid cycle, resulting in incomplete fatty acid oxidation and accumulation of β-
oxidative intermediates that may contribute to mitochondrial malfunction (16).  Considering 
these findings, palmitate treatment may trigger a compensatory increase in CS activity as an 
attempt to improve complete lipid oxidation in light of increased β-oxidative flux without 
concomitant enhancement of downstream oxidative metabolism (i.e. COX-IV protein 
abundance) due to decreased PGC1α expression.  This is further supported by the finding that 
DHA maintained PGC1α and attenuated all of these changes when added to palmitate treatment. 
     Muoio’s group demonstrated that the decrease in PGC1α expression in their high-fat-fed 
animals was associated with insulin resistance (16), and Sandri et al. noted that diabetes-related 
muscle atrophy may be triggered by insulin resistance (34).  Moreover, there is a plethora of data 
showing that saturated fatty acids are detrimental to skeletal muscle (19) and contribute to the 
formation of insulin resistance (19, 25), while exposure to unsaturated fatty acids prevents, 
attenuates, or reverses insulin resistance induced by saturated fatty acids and overnutrition (1, 4, 
8, 19, 23, 25, 28, 32, 38, 39).  Therefore, another aim of this thesis was to determine if DHA 
could attenuate the negative effects of palmitate on the insulin signaling pathway in this cell 
culture model of a high-fat environment.  We examined phosphorylation of IRS-1 on serine 
636/639, which is inhibitory to the protein We examined phosphorylation of IRS-1 on serine 
636/639, which is inhibitory to the protein {Morino, 2005 #137}, and found that all fatty acid 
treatments led to 2-3-fold increases in phosphorylation, but without significant differences 
between treatments or compared to control.  Since this measure did not offer much insight into 
the sensitivity of the insulin signaling pathway, we continued downstream of IRS-1 and 
measured protein expression and activation of three proteins in the  insulin signaling pathway, 
protein kinase B (Akt), glycogen synthase kinase (GSK) 3β, and ribosomal protein S6 (rpS6).  
Akt is a downstream substrate of IRS-1 that can directly inhibit GSK3β, removing its inhibition 
of glycogen synthase, as well as indirectly activate rpS6 and promote synthesis of proteins 
involved in cell cycle progression (13).  We also wanted to assess the responsiveness of the 
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insulin signaling pathway after treatment with the different fatty acids but did not have means to 
perform radioisotopic labeling for glucose uptake or glycogen synthesis as functional outcome 
data; therefore, Akt and GSK3β activation and total protein levels after insulin stimulation were 
measured. 
     The palmitate-induced decrease in basal and insulin-stimulated Akt activation is consistent 
with previous research from our lab that demonstrated over 30% decreases in phospho-AktSer473 
and total Akt after treatment of myotubes with 0.75mM palmitate for 16 hours followed by 10 
minutes of serum-stimulation (29).  In addition, another group found an approximate 40% 
decrease in phospho-AktSer473 upon insulin stimulation after 24 hours of palmitate treatment but 
not after treatment with oleate (a monounsaturated fatty acid) in cultured myotubes (33), 
highlighting the differential effects of unsaturated and saturated fatty acids on the insulin 
signaling pathway.  More specifically to omega-3 polyunsaturated fatty acids, previous data 
demonstrated an enhancement of insulin signaling through Akt-mTOR-S6K-4EBP1 in steers fed 
with long-chain omega-3 fatty acids (9), and our finding of increased rpS6 phosphorylation with 
addition of DHA to the palmitate treatment expands this finding, as it is a substrate of S6K. 
     Together these data support the idea that the saturated fatty acid palmitate blunted growth and 
markers of oxidative metabolism, increased intramyocellular lipid content, and caused 
unresponsiveness to very high concentrations of insulin.  However, the omega-3 polyunsaturated 
fatty acid DHA restored insulin responsiveness and cellular growth, as evidenced by the fact that 
addition of DHA attenuated the palmitate-induced changes in myotube morphology and size, 
intramyocellular lipid content, and PGC1α and COX-IV protein abundance, which was 
associated with improved basal and insulin-stimulated signaling.  While it is not a completely 
novel finding that omega-3 fatty acids improve insulin signaling in skeletal muscle, as Storlien 
and colleagues demonstrated a positive effect of fish oil on systemic insulin sensitivity in 1987 
(39), these data supports a novel theory for how long-chain omega-3 fatty acids may improve 
insulin signaling in skeletal muscle in a high fat environment.   One of the most significant 
findings was that DHA maintained PGC1α protein expression, and it is warranted to continue 
investigating whether this promotes oxidative metabolism and preserves mitochondrial mass and 





Limitations and Future Directives 
    One limitation of this study is the lack of oxidative metabolic markers compared to the amount 
necessary to draw solid conclusions.  Inclusion of a single transcription factor and only two 
markers in the entire oxidative pathway provides limited data with which to draw conclusions 
regarding the oxidative capacity of the cells after fatty acid treatment.  This is especially 
significant in this data because we saw disparate effects on our oxidative markers with a slight 
palmitate-induced increase in CS activity and no change with addition of DHA, but decreased 
palmitate-induced protein abundance of PGC1α and COX-IV, which was reversed with DHA.  
To strengthen these data, further examination of oxidative markers is required.  These 
measurements should focus on both clarifying the differential effects on enzyme activity versus 
protein expression and identifying the functional outcome of these changes (i.e. lipid oxidation 
rates).   
     CS protein expression and COX activity should be measured to complement the measurement 
of its activity and protein abundance, respectively.  The activity and protein expression of 
another tricarboxylic acid cycle enzyme, such as succinate dehydrogenase, and electron transport 
chain component, such as COX-I, could also be examined to provide a more comprehensive 
evaluation of the capacity of the tricarboxylic acid cycle and electron transport chain.  
     To identify if the maintenance of PGC1α by DHA treatment alters “functional” outcomes of 
oxidative metabolism, mitochondrial content should be quantified to confirm that the protein 
expression of PGC1α correlates to the mitochondrial content.  This would nicely complement the 
markers of mitochondrial quality (CS and cytochrome c oxidase protein expressions and 
activities) to indicate overall mitochondrial capacity.  Furthermore, lipid oxidation should also be 
measured as a functional outcome.  The argument that fatty acid treatments increase lipid 
oxidation but without matching of tricarboxylic acid cycle and electron transport chain activity 
(26) suggests that measuring both incomplete and complete lipid oxidation is required.  Previous 
data indicate that this can be accomplished by evaluating lipid incorporation into acid soluble 
metabolites (incomplete oxidation) and carbon dioxide (complete oxidation) (7, 16).  Together 
these measurements would allow for a more complete examination of the oxidative metabolic 
capacity of myotubes after treatment with saturated and polyunsaturated fatty acids and allow for 
a more solid argument to be made with respect to their differential effects. 
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     Along the same lines as functional outcomes for oxidative metabolism, measuring more 
functional markers of insulin signaling would provide a clearer idea of the actual significance of 
the basal and insulin-stimulated Akt and GSK3β protein expressions.  While there are data that 
demonstrate omega-3-related improvements in systemic insulin sensitivity in animal (8, 38, 39) 
and human models (11) of insulin resistance, we cannot assume that these changes in insulin 
signaling in cell culture models holds equal value.  Therefore, a functional measurement of 
glucose uptake, glycogen synthesis, and/or protein synthesis rate would strengthen these data. 
     As previously discussed, it is possible that palmitate treatment not only reduced AMPKα2 
protein expression, but also protein expression of the β2 subunit.  Since the α2/β2 subunit 
translocates to the nucleus to activate and enhance protein expression of PGC1α (14, 20, 40), the 
decrease of its abundance in the palmitate-treated cells could be due to loss of β2 expression, as 
well.  This possibility should be examined by measuring the total protein abundances of the β1 
and β2 subunits by Western blotting.  The data regarding phosphorylation (activation) of PGC1α 
by AMPK is limited (14), and when good antibodies for these phosphorylation sites become 
commercially available, Western blotting could also be used to further examine if the 
phosphorylation of PGC1α (indicating its activity) is altered similarly to its protein expression 
with the different fatty acid treatments. 
     Lastly, it is possible that the methods used in the cell culture model itself could be a limitation 
to this study.  Recently Muoio’s group published data suggesting that cell culture experiments 
examining the effects of fatty acid treatments on metabolic makers should include supplemental 
carnitine in the culture culture media (17).  Carnitine is necessary for the formation of long chain 
acyl-carnitines from fatty acyl-CoA by carnitine palmitoyl transferase-1 in order to enter the 
mitochondria for β-oxidation (35).  Since carnitine is synthesized in the liver, storage of carnitine 
in cultured skeletal muscles is very low which can restrict β-oxidation (17).  Therefore, future 
studies examining the effects of saturated versus polyunsaturated fatty acids should include 
supplemental carnitine in the media in order to allow for physiologically normal β-oxidation to 
occur.  This would ensure that any changes in β-oxidation with the different fatty acids would 
not be simply due to a decrease in necessary precursors for lipid oxidation.    
 
 





1. Aas V, Rokling-Andersen MH, Kase ET, Thoresen GH, and Rustan AC. 
Eicosapentaenoic acid (20:5 n-3) increases fatty acid and glucose uptake in cultured 
human skeletal muscle cells. J Lipid Res 47: 366-374, 2006. 
2. Benton CR, Nickerson JG, Lally J, Han XX, Holloway GP, Glatz JF, Luiken JJ, 
Graham TE, Heikkila JJ, and Bonen A. Modest PGC-1alpha overexpression in muscle 
in vivo is sufficient to increase insulin sensitivity and palmitate oxidation in 
subsarcolemmal, not intermyofibrillar, mitochondria. The Journal of biological chemistry 
283: 4228-4240, 2008. 
3. Canto C and Auwerx J. PGC-1alpha, SIRT1 and AMPK, an energy sensing network 
that controls energy expenditure. Current opinion in lipidology 20: 98-105, 2009. 
4. D'Alessandro ME, Lombardo YB, and Chicco A. Effect of dietary fish oil on insulin 
sensitivity and metabolic fate of glucose in the skeletal muscle of normal rats. Ann Nutr 
Metab 46: 114-120, 2002. 
5. Dimopoulos N, Watson M, Sakamoto K, and Hundal HS. Differential effects of 
palmitate and palmitoleate on insulin action and glucose utilization in rat L6 skeletal 
muscle cells. The Biochemical journal 399: 473-481, 2006. 
6. Flachs P, Mohamed-Ali V, Horakova O, Rossmeisl M, Hosseinzadeh-Attar MJ, 
Hensler M, Ruzickova J, and Kopecky J. Polyunsaturated fatty acids of marine origin 
induce adiponectin in mice fed a high-fat diet. Diabetologia 49: 394-397, 2006. 
7. Gaster M. Reduced lipid oxidation in myotubes established from obese and type 2 
diabetic subjects. Biochemical and biophysical research communications 382: 766-770, 
2009. 
8. Ghafoorunissa, Ibrahim A, Rajkumar L, and Acharya V. Dietary (n-3) long chain 
polyunsaturated fatty acids prevent sucrose-induced insulin resistance in rats. J Nutr 135: 
2634-2638, 2005. 
9. Gingras AA, White PJ, Chouinard PY, Julien P, Davis TA, Dombrowski L, Couture 
Y, Dubreuil P, Myre A, Bergeron K, Marette A, and Thivierge MC. Long-chain 
omega-3 fatty acids regulate bovine whole-body protein metabolism by promoting 
muscle insulin signalling to the Akt-mTOR-S6K1 pathway and insulin sensitivity. J 
Physiol 579: 269-284, 2007. 
10. Guo ZK and Jensen MD. Accelerated intramyocellular triglyceride synthesis in skeletal 
muscle of high-fat-induced obese rats. Int J Obes Relat Metab Disord 27: 1014-1019, 
2003. 
11. Haugaard SB, Madsbad S, Hoy CE, and Vaag A. Dietary intervention increases n-3 
long-chain polyunsaturated fatty acids in skeletal muscle membrane phospholipids of 
obese subjects. Implications for insulin sensitivity. Clin Endocrinol (Oxf) 64: 169-178, 
2006. 
12. Holloway GP, Benton CR, Mullen KL, Yoshida Y, Snook LA, Han XX, Glatz JF, 
Luiken JJ, Lally J, Dyck DJ, and Bonen A. In obese rat muscle transport of palmitate 
is increased and is channeled to triacylglycerol storage despite an increase in 
mitochondrial palmitate oxidation. American journal of physiology 296: E738-747, 2009. 
13. Hresko RC and Mueckler M. mTOR.RICTOR is the Ser473 kinase for Akt/protein 




14. Jager S, Handschin C, St-Pierre J, and Spiegelman BM. AMP-activated protein 
kinase (AMPK) action in skeletal muscle via direct phosphorylation of PGC-1alpha. 
Proceedings of the National Academy of Sciences of the United States of America 104: 
12017-12022, 2007. 
15. Kinkel AD, Fernyhough ME, Helterline DL, Vierck JL, Oberg KS, Vance TJ, 
Hausman GJ, Hill RA, and Dodson MV. Oil red-O stains non-adipogenic cells: a 
precautionary note. Cytotechnology 46: 49-56, 2004. 
16. Koves TR, Li P, An J, Akimoto T, Slentz D, Ilkayeva O, Dohm GL, Yan Z, Newgard 
CB, and Muoio DM. Peroxisome proliferator-activated receptor-gamma co-activator 
1alpha-mediated metabolic remodeling of skeletal myocytes mimics exercise training and 
reverses lipid-induced mitochondrial inefficiency. The Journal of biological chemistry 
280: 33588-33598, 2005. 
17. Koves TR, Ussher JR, Noland RC, Slentz D, Mosedale M, Ilkayeva O, Bain J, 
Stevens R, Dyck JR, Newgard CB, Lopaschuk GD, and Muoio DM. Mitochondrial 
overload and incomplete fatty acid oxidation contribute to skeletal muscle insulin 
resistance. Cell metabolism 7: 45-56, 2008. 
18. Le Foll C, Corporeau C, Le Guen V, Gouygou JP, Berge JP, and Delarue J. Long-
chain n-3 polyunsaturated fatty acids dissociate phosphorylation of Akt from 
phosphatidylinositol 3'-kinase activity in rats. American journal of physiology 292: 
E1223-1230, 2007. 
19. Lee JS, Pinnamaneni SK, Eo SJ, Cho IH, Pyo JH, Kim CK, Sinclair AJ, Febbraio 
MA, and Watt MJ. Saturated, but not n-6 polyunsaturated, fatty acids induce insulin 
resistance: role of intramuscular accumulation of lipid metabolites. J Appl Physiol 100: 
1467-1474, 2006. 
20. Lee WJ, Kim M, Park HS, Kim HS, Jeon MJ, Oh KS, Koh EH, Won JC, Kim MS, 
Oh GT, Yoon M, Lee KU, and Park JY. AMPK activation increases fatty acid 
oxidation in skeletal muscle by activating PPARalpha and PGC-1. Biochemical and 
biophysical research communications 340: 291-295, 2006. 
21. Liu S, Baracos VE, Quinney HA, and Clandinin MT. Dietary omega-3 and 
polyunsaturated fatty acids modify fatty acyl composition and insulin binding in skeletal-
muscle sarcolemma. The Biochemical journal 299 ( Pt 3): 831-837, 1994. 
22. Liu Y, Wan Q, Guan Q, Gao L, and Zhao J. High-fat diet feeding impairs both the 
expression and activity of AMPKa in rats' skeletal muscle. Biochemical and biophysical 
research communications 339: 701-707, 2006. 
23. Lombardo YB, Hein G, and Chicco A. Metabolic syndrome: effects of n-3 PUFAs on a 
model of dyslipidemia, insulin resistance and adiposity. Lipids 42: 427-437, 2007. 
24. Malenfant P, Tremblay A, Doucet E, Imbeault P, Simoneau JA, and Joanisse DR. 
Elevated intramyocellular lipid concentration in obese subjects is not reduced after diet 
and exercise training. American journal of physiology 280: E632-639, 2001. 
25. Montell E, Turini M, Marotta M, Roberts M, Noe V, Ciudad CJ, Mace K, and 
Gomez-Foix AM. DAG accumulation from saturated fatty acids desensitizes insulin 
stimulation of glucose uptake in muscle cells. American journal of physiology 280: E229-
237, 2001. 
26. Muoio DM and Koves TR. Lipid-induced metabolic dysfunction in skeletal muscle. 
Novartis Foundation symposium 286: 24-38; discussion 38-46, 162-163, 196-203, 2007. 
44 
 
27. Muoio DM and Koves TR. Skeletal muscle adaptation to fatty acid depends on 
coordinated actions of the PPARs and PGC1 alpha: implications for metabolic disease. 
Applied physiology, nutrition, and metabolism = Physiologie appliquee, nutrition et 
metabolisme 32: 874-883, 2007. 
28. Mustad VA, Demichele S, Huang YS, Mika A, Lubbers N, Berthiaume N, 
Polakowski J, and Zinker B. Differential effects of n-3 polyunsaturated fatty acids on 
metabolic control and vascular reactivity in the type 2 diabetic ob/ob mouse. Metabolism 
55: 1365-1374, 2006. 
29. Peterson JM, Wang Y, Bryner RW, Williamson DL, and Alway SE. Bax signaling 
regulates palmitate-mediated apoptosis in C(2)C(12) myotubes. American journal of 
physiology 295: E1307-1314, 2008. 
30. Pimenta AS, Gaidhu MP, Habib S, So M, Fediuc S, Mirpourian M, Musheev M, 
Curi R, and Ceddia RB. Prolonged exposure to palmitate impairs fatty acid oxidation 
despite activation of AMP-activated protein kinase in skeletal muscle cells. Journal of 
cellular physiology 217: 478-485, 2008. 
31. Roden M. Muscle triglycerides and mitochondrial function: possible mechanisms for the 
development of type 2 diabetes. International journal of obesity (2005) 29 Suppl 2: S111-
115, 2005. 
32. Rossi AS, Lombardo YB, Lacorte JM, Chicco AG, Rouault C, Slama G, and 
Rizkalla SW. Dietary fish oil positively regulates plasma leptin and adiponectin levels in 
sucrose-fed, insulin-resistant rats. Am J Physiol Regul Integr Comp Physiol 289: R486-
R494, 2005. 
33. Sabin MA, Stewart CE, Crowne EC, Turner SJ, Hunt LP, Welsh GI, Grohmann 
MJ, Holly JM, and Shield JP. Fatty acid-induced defects in insulin signalling, in 
myotubes derived from children, are related to ceramide production from palmitate rather 
than the accumulation of intramyocellular lipid. Journal of cellular physiology 211: 244-
252, 2007. 
34. Sandri M, Lin J, Handschin C, Yang W, Arany ZP, Lecker SH, Goldberg AL, and 
Spiegelman BM. PGC-1alpha protects skeletal muscle from atrophy by suppressing 
FoxO3 action and atrophy-specific gene transcription. Proceedings of the National 
Academy of Sciences of the United States of America 103: 16260-16265, 2006. 
35. Schrauwen P. High-fat diet, muscular lipotoxicity and insulin resistance. Proc Nutr Soc 
66: 33-41, 2007. 
36. Simoncikova P, Wein S, Gasperikova D, Ukropec J, Certik M, Klimes I, and 
Sebokova E. Comparison of the extrapancreatic action of gamma-linolenic acid and n-3 
PUFAs in the high fat diet-induced insulin resistance [corrected]. Endocr Regul 36: 143-
149, 2002. 
37. Stevenson EJ, Koncarevic A, Giresi PG, Jackman RW, and Kandarian SC. 
Transcriptional profile of a myotube starvation model of atrophy. J Appl Physiol 98: 
1396-1406, 2005. 
38. Storlien LH, Jenkins AB, Chisholm DJ, Pascoe WS, Khouri S, and Kraegen EW. 
Influence of dietary fat composition on development of insulin resistance in rats. 
Relationship to muscle triglyceride and omega-3 fatty acids in muscle phospholipid. 
Diabetes 40: 280-289, 1991. 
45 
 
39. Storlien LH, Kraegen EW, Chisholm DJ, Ford GL, Bruce DG, and Pascoe WS. Fish 
oil prevents insulin resistance induced by high-fat feeding in rats. Science 237: 885-888, 
1987. 
40. Suzuki A, Okamoto S, Lee S, Saito K, Shiuchi T, and Minokoshi Y. Leptin stimulates 
fatty acid oxidation and peroxisome proliferator-activated receptor alpha gene expression 
in mouse C2C12 myoblasts by changing the subcellular localization of the alpha2 form of 
AMP-activated protein kinase. Mol Cell Biol 27: 4317-4327, 2007. 
41. Taouis M, Dagou C, Ster C, Durand G, Pinault M, and Delarue J. N-3 
polyunsaturated fatty acids prevent the defect of insulin receptor signaling in muscle. 
American journal of physiology 282: E664-671, 2002. 
42. Turner N, Bruce CR, Beale SM, Hoehn KL, So T, Rolph MS, and Cooney GJ. 
Excess lipid availability increases mitochondrial fatty acid oxidative capacity in muscle: 
evidence against a role for reduced fatty acid oxidation in lipid-induced insulin resistance 
in rodents. Diabetes 56: 2085-2092, 2007. 
43. Unger RH. Minireview: weapons of lean body mass destruction: the role of ectopic 
lipids in the metabolic syndrome. Endocrinology 144: 5159-5165, 2003. 
44. Viollet B, Lantier L, Devin-Leclerc J, Hebrard S, Amouyal C, Mounier R, Foretz M, 
and Andreelli F. Targeting the AMPK pathway for the treatment of Type 2 diabetes. 
Front Biosci 14: 3380-3400, 2009. 
45. Wang X, Zhou L, Li G, Luo T, Gu Y, Qian L, Fu X, Li F, Li J, and Luo M. Palmitate 
activates AMP-activated protein kinase and regulates insulin secretion from beta cells. 
Biochemical and biophysical research communications 352: 463-468, 2007. 
46. Williamson DL, Butler DC, and Alway SE. AMPK inhibits myoblast differentiation 





Figure 1. Dose-response curves for activation of AMPK following palmitate and cis-4, 7, 10, 13, 
16, 19-docosahexaenoic acid (DHA) treatments.  Cells were incubated in medium containing 2% 
fetal calf serum, 2% bovine serum albumin, and the indicated fatty acid concentrations for 24 
hours.  Cells were harvested by scraping in 1X SDS-containing sample buffer, and samples were 
analyzed for phosphorylation of AMPK on Thr172 and total AMPKα and were normalized to β-
tubulin.  Representative Western blots are shown. 
Figure 2.  Myotube morphology and diameter are differentially altered with palmitate versus 
DHA treatment.  Cells were incubated in medium containing 2% fetal calf serum, 2% bovine 
serum albumin, and either no fatty acids (Control), 0.5mM palmitate, 0.1mM cis-4, 7, 10, 13, 16, 
19-docosahexaenoic acid (DHA), or 0.1mM DHA plus 0.5mM palmitate for 24, 48, or 96 hours.  
Fresh media was supplied after 48 hours. A) Images of myotubes after indicated treatment 
durations were collected via computer-integrated camera connected to a microscope at x10.  B) 
Myotube diameter of treated cells.  Six diameters per myotube from ~10 myotubes (per culture) 
from three wells per treatment condition that were treated for 48 and 96 hours with palmitate, 
DHA, DHA+palmitate, or no fatty acids. *Denotes p≤0.05 versus other 48h treatment conditions; 
§Denotes p<0.00 versus other 96h treatment conditions; **Denotes p<0.05 versus 96h control 
conditions. 
Figure 3.  DHA attenuates the reduced total AMPKα protein expression and the increased 
AMPK ratio observed with palmitate treatment.  Cells were incubated in medium containing 2% 
fetal calf serum, 2% bovine serum albumin, and either no fatty acids (Control), 0.5mM palmitate, 
0.1mM DHA, or 0.1mM cis-4, 7, 10, 13, 16, 19-docosahexaenoic acid (DHA) plus 0.5mM 
palmitate for 96 hours with fresh media supplied after 48 hours. Cells were harvested by scraping 
in 1X SDS-containing sample buffer, and samples were analyzed for protein expression and 
normalized to glyceraldehydes-3-phosphate dehydrogenase (GAPDH) protein expression. 
Representative Western blots are shown.  A) Phosphorylation of AMPK on Thr172 was not 
different between treatments, but co-treatment of DHA+Palmitate increased total AMPKα and 
attenuated the increased AMPK ratio observed with palmitate treatment. B) No significant 
differences were observed in phosphorylation of ACC on serine79, total ACC protein expression, 
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or the ACC ratio.  *Denotes p≤0.05 versus palmitate conditions for total AMPKα. §Denotes 
p<0.05 versus all other conditions for the AMPK ratio. 
Figure 4. Palmitate treatment increases intramyocellular lipid content.  Cells were incubated in 
medium containing 2% fetal calf serum, 2% bovine serum albumin, and either no fatty acids 
(Control), 0.5mM palmitate, 0.1mM cis-4, 7, 10, 13, 16, 19-docosahexaenoic acid  (DHA), or 
0.1mM DHA plus 0.5mM palmitate for 96 hours with fresh media supplied after 48 hours.  After 
treatment, cells were treated with a 36% Oil red O/triethyl phosphate solution that stains all 
neutral intramyocellular lipids and autofluoresces.  Fluorescence was measured (excitation 
485nm, emission 530nm) and normalized to average protein content per treatment. *Denotes 
p<0.0001 versus all other conditions. 
Figure 5. DHA maintains markers of oxidative metabolism in palmitate-treated cells.  Cells were 
incubated in medium containing 2% fetal calf serum, 2% bovine serum albumin, and either no 
fatty acids (Control), 0.5mM palmitate, 0.1mM cis-4, 7, 10, 13, 16, 19-docosahexaenoic acid  
(DHA), or 0.1mM DHA plus 0.5mM palmitate for 96 hours with fresh media supplied after 48 
hours. For analysis of protein expression, cells were harvested by scraping in 1X SDS-containing 
sample buffer and subjected to Western blotting.  Expression was normalized to 
glyceraldehydes-3-phosphate dehydrogenase (GAPDH) protein expression. Representative 
Western blots are shown. A) Protein expression of peroxisome proliferator-activated receptor 
gamma coactivator 1α (PGC1α) is increased by adding DHA to palmitate treatment. *Denotes 
p<0.05 versus palmitate condition. B) Citrate synthase (CS) activity.  Treated cells were lysed 
with CellLytic M and mixed with acetyl coenzyme A, oxaloacetic acid, and 5-thio-2-
nitrobenzioc acid to spectrophotometrically measure CS activity by reading absorbance at 
412nm. §Denotes p<0.05 versus all other conditions. C) Cytochrome c oxidase subunit IV (COX-
IV) protein expression is not significantly altered with different fatty acid treatments. 
Figure 6. Phosphorylation of IRS-1 is not different between palmitate and DHA treatments. 
Cells were incubated in medium containing 2% fetal calf serum, 2% bovine serum albumin, and 
either no fatty acids (Control), 0.5mM palmitate, 0.1mM cis-4, 7, 10, 13, 16, 19-
docosahexaenoic acid  (DHA), or 0.1mM DHA plus 0.5mM palmitate for 96 hours with fresh 
media supplied after 48 hours. Cells were harvested by scraping in 1X SDS-containing sample 
buffer and analyzed for protein expression of IRS-1 phosphorylation on serine636/639 and 
48 
 
normalized to glyceraldehydes-3-phosphate dehydrogenase (GAPDH) protein expression. 
Representative Western blots are shown. 
Figure 7.  DHA treatment attenuates the palmitate-induced decrease in basal insulin signaling.  
Cells were incubated in medium containing 2% fetal calf serum, 2% bovine serum albumin, and 
either no fatty acids (Control), 0.5mM palmitate, 0.1mM cis-4, 7, 10, 13, 16, 19-
docosahexaenoic acid  (DHA), or 0.1mM DHA plus 0.5mM palmitate for 96 hours with fresh 
media supplied after 48 hours. Cells were harvested by scraping in 1X SDS-containing sample 
buffer and analyzed for protein expression Akt and GSK3β normalized to glyceraldehydes-3-
phosphate dehydrogenase (GAPDH) protein expression. A)  Representative Western blots for 
phospho-AktSer473, phospho-GSK3βSer9, total Akt and GSK3β.  B) Basal phospho- and total Akt 
levels were not statistically different between treatments. C) Addition of DHA attenuated the 
decrease in basal phosphorylation of GSK3βSer9 seen with palmitate treatment, but total GSK3β 
expression was unchanged. *Denotes p<0.05 versus DHA conditions. 
Figure 8. DHA treatment attenuates the palmitate-induced decrease in basal activation of 
ribosomal protein S6 (rpS6). Cells were incubated in medium containing 2% fetal calf serum, 2% 
bovine serum albumin, and either no fatty acids (Control), 0.5mM palmitate, 0.1mM cis-4, 7, 10, 
13, 16, 19-docosahexaenoic acid  (DHA), or 0.1mM DHA plus 0.5mM palmitate for 96 hours 
with fresh media supplied after 48 hours. Cells were harvested by scraping in 1X SDS-
containing sample buffer and analyzed for phosphorylation of rpS6 on Ser240/244 and 
normalized to glyceraldehydes-3-phosphate dehydrogenase (GAPDH) protein expression. 
Representative Western blots are shown. *Denotes p<0.05 versus palmitate condition. 
Figure 9. DHA treatment attenuates the palmitate-induced decrease in insulin-stimulated 
activation of signaling proteins.  Cells were incubated in medium containing 2% fetal calf serum, 
2% bovine serum albumin, and either no fatty acids (Control), 0.5mM palmitate, 0.1mM cis-4, 7, 
10, 13, 16, 19-docosahexaenoic acid  (DHA), or 0.1mM DHA plus 0.5mM palmitate for 96 
hours with fresh media supplied after 48 hours.  Cells were stimulated with 100nM insulin for 15 
minutes then harvested by scraping in 1X SDS-containing sample buffer and analyzed for 
protein expression Akt and GSK3β normalized to glyceraldehydes-3-phosphate dehydrogenase 
(GAPDH) protein expression. A) Representative Western blots for phospho-AktSer473, phospho-
GSK3βSer9, total Akt and GSK3β with insulin stimulation.  B) DHA attenuates the palmitate-
49 
 
induced decrease in insulin-stimulated total Akt protein expression. *Denotes p<0.05 versus all 
other conditions. C) DHA attenuates the palmitate-induced decrease in insulin-stimulated 
phosphorylation of GSK3βSer9 and the ratio of phospho- to total GSK3β. †Denotes p<0.05 
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